Also found in: Dictionary, Thesaurus, Medical, Encyclopedia, Wikipedia.
Related to relapsing: relapsing fever
See: regressive
References in periodicals archive ?
Whether we are likely to see the reemergence of this disease is difficult to predict because we do not understand relapsing fever borreliae and their complex host interactions.
AVONEX is the world's leading treatment for relapsing forms of multiple sclerosis.
Tick-borne relapsing fever caused by Borrelia hermsii, Montana.
Obtaining cultures or performing histochemical staining can help rule out infectious organisms, while clinical tests for cartilage matrix proteins or antibodies to type II collagen (found uniquely in cartilage) can help define relapsing polychondritis.
The 788-bp sequence was aligned with sequences of other Borrelia species representing the LB and relapsing fever clades, and phylogenetic analysis was conducted.
In North America, Lyme disease and endemic relapsing fever pose the greatest threat to human health and have received the most attention of the borrelial diseases.
Therapy should begin as soon as possible following a definite diagnosis of MS and determination of a relapsing course.
The FDA cleared the interferon drugs Betaseron and Avonex only for use in relapsing forms of MS because there were no scientific facts on the effects of these new drugs in progressive MS.
and DUBLIN, Ireland -- Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) today announced the commercial availability of TYSABRI(R) (natalizumab) for the treatment of relapsing forms of multiple sclerosis (MS) in the U.
ZUG, Switzerland & DUBLIN, Ireland -- Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) today announced that they received approval from the European Commission to market TYSABRI(R) (natalizumab) as a treatment for relapsing remitting multiple sclerosis (MS) to delay the progression of disability and reduce the frequency of relapses.
AVONEX is the most prescribed treatment for relapsing forms of multiple sclerosis worldwide (through November 2005), with more than 130,000 patients on therapy.